bioRxiv · 10.1101/648709
High-throughput identification of genes involved in single and multi-drug resistance in pancreatic cancer with pooled CRISPR screening
Abstract
Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes in part due to therapeutic resistance. We conducted four genome-wide CRISPR activation (CRISPRact) and CRISPR knock out (CRISPRko) screens to identify novel resistance mechanisms to four cytotoxic chemotherapies (gemcitabine, 5-fluorouracil, irinotecan, and oxaliplatin). ABCG2, a well-described efflux pump was the strongest mediator of resistance. We showed that overexpressing HDAC1 altered promoter occupancy and expression of genes involved in the epithelial-to-mesenchymal transition. Using the results of our CRISPR screens, we predicted drug sensitivity for patients and cell lines based on gene expression profiles. These predictions could be clinically useful for treatment selection.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Ramaker, R. C., Hardigan, A. A., Gordon, E. R., Myers, R. M., Cooper, S. J.. 2019-05-30. High-throughput identification of genes involved in single and multi-drug resistance in pancreatic cancer with pooled CRISPR screening. https://doi.org/10.1101/648709
Cite the original work for its findings. Save a collection to share your selection of sources.